PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

EMEND (ALL PRODUCTS)
(aprepitant)

EMEND (ALL PRODUCTS)
(fosaprepitant dimeglumine)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization

POLICY
FDA-APPROVED INDICATIONS
Emend (aprepitant) capsules and oral suspension
Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
Emend for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Emend capsules, in combination with other antiemetic agents, is indicated in patients 12 years of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Prevention of Postoperative Nausea and Vomiting (PONV)
Emend capsules are indicated in adults for the prevention of postoperative nausea and vomiting.
Limitations of Use

- Emend has not been studied for the treatment of established nausea and vomiting.
- Chronic continuous administration of Emend is not recommended because it has not been studied and because the drug interaction profile may change during chronic continuous use.

Emend (fosaprepitant dimeglumine) for injection
Emend for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use

- Emend has not been studied for the treatment of established nausea and vomiting.

COVERAGE CRITERIA
The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the prevention of nausea and vomiting associated with highly or moderately emetogenic chemotherapy AND will be used in combination with other antiemetic agents
  OR
- Emend capsules are being prescribed for the prevention of postoperative nausea and vomiting

Quantity Limits apply.

LIMIT CRITERIA

Drug	Quantities to approve
Emend 80 mg Capsules	16 capsules / 21 days
Emend 125 mg Capsules	4 capsules / 21 days
Emend Tri-pack (contains one 125 mg capsule and two 80 mg capsules)	4 packs / 21 days
Emend 125 mg for Oral Suspension (Single-Dose Kit)	12 kits / 21 days
Emend 150 mg Injection	4 vials / 21 days
Emend 40 mg Capsule	6 capsules / 6 months

**** This drug is indicated for short-term acute use; therefore, the mail limit will be the same as the retail limit.*** *The duration of 21 days is used for a 28-day fill period.*

REFERENCES

1. Emend capsules and oral suspension [package insert]. Whitehouse Station, NJ: Merck and Co., Inc; May 2017.
2. Emend for injection [package insert]. Whitehouse Station, NJ: Merck and Co., Inc; August 2017.
3. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed January 2018.
4. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed January 2018.
5. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Antiemesis. V.2.2017. Available at: www.nccn.org. Accessed January 2018.